La marca DEMONSTRate: Drug Evalutation in Melanoma: ONcology STudy and Research of Ipilimumab, fundada en 2010 (Estados Unidos de América), a 496 marcas hermanas y 17478 marcas de la competencia. DEMONSTRate: Drug Evalutation in Melanoma: ONcology STudy and Research of Ipilimumab es una marca de BRISTOL-MYERS SQUIBB COMPANY, que cotiza en la bolsa de valores de New York. DEMONSTRate: Drug Evalutation in Melanoma: ONcology STudy and Research of Ipilimumab pertenece al sector empresarial Fabricantes de medicamentos.
Toda la actualidad 
BRISTOL-MYERS SQUIBB COMPANY
(DEMONSTRate: Drug Evalutation in Melanoma: ONcology STudy and Research of Ipilimumab)
Bolsa de valores: más información sobre BRISTOL-MYERS SQUIBB COMPANY
(DEMONSTRate: Drug Evalutation in Melanoma: ONcology STudy and Research of Ipilimumab)
